Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: CrazyPete who wrote (9397)	4/16/2006 3:46:37 PM
From: Rocky9	Read Replies (1) \| Respond to of 10280

I don't think that it is wrong. It is not a typo. If you add the weeklies for the 13 weeks in Q4, you get 1,428,438. The monthlies added to a total of 1,521,342. If you add the weeklies for the 13 weeks in Q1, you get 1,531,806. If there is the same % undercounting in the weeklies, you get 1,631,433 for this quarter. Since Feb. is a short month, and both Jan. and Feb. have a holiday in them, ~560,000 for March looks right to me. The quarterly number is the important one. If there is 6.5% growth in the number of Rxs and a 9% price increase, we might see ~15% revenue growth for Lun. Stocking is the unknown. The other big unknowns are R&D and marketing. R&D has been consistently under guidance. Marketing has been over guidance. I would not be surprised to see another big upside surprise in earnings. I doubt that we will see the market move big time though. Too many uncertainties with Xop and NBIX/PFE.